Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure

Journal of Pathology

Volumn 205, Issue 5, 2005, Pages 558-564

  Powell, Ned ^a   Jeremiah, Steve ^a   Morishita, Mariko ^b   Dudley, Ed ^a   Bethel, Jackie ^a   Bogdanova, Tetyana ^c   Tronko, Mykola ^c   Thomas, Gerry ^a,d  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b NAGASAKI UNIVERSITY   (Japan)

^c INSTITUTE OF ENDOCRINOLOGY   (Ukraine)

^d SINGLETON HOSPITAL   (United Kingdom)

Author keywords

BRAF T1796A; Chernobyl; MALDI TOF MS; Mutation; Radiation; Thyroid cancer

Indexed keywords

ADENINE; B RAF KINASE; DNA; PARAFFIN; RADIOACTIVE IODINE; RESTRICTION ENDONUCLEASE; TYROSINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER PATIENT; CHERNOBYL ACCIDENT; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA EXTRACTION; ENZYME ANALYSIS; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICRODISSECTION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIATION EXPOSURE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THYROID PAPILLARY CARCINOMA; TISSUE SECTION; UKRAINE;

ACCIDENTS, RADIATION; ADOLESCENT; ADULT; AGE FACTORS; AGED; CARCINOMA, PAPILLARY; CHILD; GENE REARRANGEMENT; HUMANS; MIDDLE AGED; MUTATION; NEOPLASMS, RADIATION-INDUCED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; UKRAINE;

EID: 17144394374     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1736     Document Type: Article

References (30)

1. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95: 625-627.
2. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457.
3. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22: 4578-4580.
4. Nikiforova MN, Ciampi R, Salvatore G, et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 2004; 209 1-6.
5. Lima J, Trovisco V, Soares P, et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 4267-4271.
6. Kumagai A, Namba H, Saenko VA, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 4280-4284.
7. Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 1995; 55: 5617-5620.
8. Thomas GA, Bunnell H, Cook HA, et al. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 1999; 84 4232-4238.
9. Smida J, Salassidis K, Hieber L, et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer 1999; 80: 32-38.
10. Harach HR, Williams ED. Childhood thyroid cancer in England and Wales. Br J Cancer 1995; 72: 777-783.
11. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997; 57: 1690-1694.
12. Williams ED, Abrosimov A, Bogdanova T, et al. Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. Br J Cancer 2004; 90: 2219-2224.
13. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
14. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63: 4561-4567.
15. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, T1796A, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88: 4393-4397.
16. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399-5404.
17. Powell NG, Dudley E, Morishita N, Bogdanova T, Tronko M, Thomas GA. Single nucleotide polymorphism analysis in the human phosphatase PTPrj gene using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 2249-2254.
18. Puxeddu E, Moretti S, Elisei R, et al. BRAF(T1796A) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 2414-2420.
19. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004; 202: 247-251.
20. Sun X, Ding H, Hung K, Guo B. A new MALDI-TOF based mini-sequencing assay for genotyping of SNPS. Nucleic Acids Res 2000; 28: E68.
21. Wise CA, Paris M, Morar B, Wang W, Kalaydjieva L, Bittles AH. A standard protocol for single nucleotide primer extension in the human genome using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2003; 17: 1195-1202.
22. Muir C, Waterhouse J, Mack T, Powell J, Whelan S. Cancer Incidence in Five Countries, Vol 5. IARC Scientific Publications No 120. International Agency for Research on Cancer: Lyon, 1987.
23. Likhtarev IA, Sobolev BG, Kairo IA, et al. Thyroid cancer in the Ukraine. Nature 1995; 375: 365.
24. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995; 141: 259-277.
25. Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63: 5209-5212.
26. Xing M, Vasko V, Tallini G, et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004; 89: 1365-1368.
27. Williams GH, Rooney S, Thomas GA, Cummins G, Williams ED. RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival-nested material. Br J Cancer 1996; 74: 585-589.
28. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 2000; 85: 1170-1175.
29. Eppenberger-Castori S, Moore DH Jr, Thor AD, et al. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 2002; 34: 1318-1330.
30. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in young women: clinicopathological features and biological specificity. Breast 2003; 12: 247-250.